12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more3rd October 2019
A lifetime model evaluating the financial, health and social impact of multigene testing at diagnosis for all breast cancer patients was found to save lives and be extremely cost-effective for both UK and US health systems.
Read more30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more13th September 2019
Researchers are calling for population-wide BRCA testing in the Jewish community after finding it to be more effective than current approaches, cost effective and to have a high satisfaction rate with those undergoing testing.
Read more4th July 2019
Dr Oliver Pearce has received a Cancer Research UK Career Establishment Award, which will fund a project that will look at restoring response to immunotherapy in triple-negative breast cancer.
Read more4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more